Rec'd PCT/PID 09 JAN 2006 PATENT COOPERA

From the

INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

JANE MASSEY LICATA LICATA & TYRELL P.C. 66 E. MAIN STREET MARLTON, NJ 08053

PCT

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY **EXAMINATION REPORT**

(PCT Rule 71.1)

Date of Mailing

(day/month/year) 24 JUN 2015

Applicant's or agent's file reference

International application No.

PENN-0858

IMPORTANT NOTIFICATION

International filing date (day/month/year)

Priority date (day/month/year)

PCT/US03/33022

17 October 2003 (17.10.2003)

17 October 2002 (17.10.2002)

Applicant

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

- The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
- A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US

Mail Stop PCT, Attn: IPEA/ US Commissioner for Patents P.O. Box 1450

Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230


Authorized officer

Sreeni Padmanabhan

Telephone No. 571.272.1600

Januce 3

Form PCT/IPEA/416 (July 1992)



PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PENN-0858	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)		
International application No.	International filing date (day/mor	nth/year) Priority date (day/month/year)		
PCT/US03/33022	17 October 2003 (17.10.2003)	17 October 2002 (17.10.2002)		
International Patent Classification (IPC) o				
IPC(7): A61K 31/55, 31/54 and US C1: 5	14/221, 213, 2245, 224.2, 301			
Applicant				
THE TRUSTEES OF THE UNIVERSITY	OF PENNSYLVANIA			
 This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36. This REPORT consists of a total of sheets, including this cover sheet. 				
2. This REPORT consists of a	total of sheets, including the	his cover sheet.		
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of sheets.				
3. This report contains indications relating to the following items:				
I Basis of the report II Priority				
III Non-establishment of report with regard to novelty, inventive step and industrial applicability				
IV Lack of unity of invention				
V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement				
VI Certain documents cited				
VII Certain defects in the international application				
VIII Certain observations on the international application				
Date of submission of the demand		f completion of this report		
12 May 2004 (12.05.2004)		31 May 2005 (31.05.2005)		
Name and mailing address of the IPEA/US	Authori	zed officer		
Mail Stop PCT, Attn: IPEA/ US Commissioner for Patents		Padmanabhan Gaille Ford		
P.O. Box 1450 Alexandria, Virginia 22313-1450		one No. 571.272.1600		
Facsimile No. (703) 305-3230 orm PCT/IPEA/409 (cover sheet)(July 1998)				



Internationa	ication No.
PCT/US03/33022	2

I.	I. Basis of the report			
1.	Wit	h regard to the elements of the international application:*		
	\boxtimes	the international application as originally filed.		
İ	\overline{X}	the description:		
1		pages 1-33 as originally filed		
		pages NONE , filed with the demand		
	N	pages NONE , filed with the letter of		
j	K	the claims:		
		pages 34 and 35, as originally filed pages NONE, as amended (together with any statement) under Article 19		
[pages NONE , filed with the demand		
		pages NONE, filed with the letter of		
l	\boxtimes	the drawings:		
ŀ		pages NONE, as originally filed		
		pages NONE, filed with the demand pages NONE, filed with the letter of		
		•		
	Ш	the sequence listing part of the description:		
		pages NONE, as originally filed pages NONE, filed with the demand		
		pages NONE , filed with the letter of		
2.	Witl	n regard to the language, all the elements marked above were available or furnished to this Authority in the		
	lang	uage in which the international application was filed, unless otherwise indicated under this item.		
	The	se elements were available or furnished to this Authority in the following language which is:		
	Щ	the language of a translation furnished for the purposes of international search (under Rule23.1(b)).		
	Щ	the language of publication of the international application (under Rule 48.3(b)).		
	Ш	the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).		
		regard to any nucleotide and/or amino acid sequence disclosed in the international application, the national preliminary examination was carried out on the basis of the sequence listing:		
		contained in the international application in printed form.		
		filed together with the international application in computer readable form.		
		furnished subsequently to this Authority in written form.		
	П	furnished subsequently to this Authority in computer readable form.		
		The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the		
	_	international application as filed has been furnished.		
١		The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.		
4. [The amendments have resulted in the cancellation of		
		the description, pages <u>NONE</u>		
		the claims, Nos. NonE		
		the drawings, sheets/fig NONE		
5. [This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**		
Re	place	ment sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in		
his report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17). ** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.				
· A	iy rej	nucement sneet containing such umenuments must be rejerred to under tiem 1 and annexed to this report.		
		i		
	~~~	DEA/400 (Dev. D./Inde. 1009)		

Form PCT/IPEA/409 (Box I) (July 1998)



International Control No.
PCT/US03/3.

2. CITATIONS ANI Claims 1-8 lack of nove 6,117,866 or 5,576, 328 US 6,117,866 discloses aggregation or disorder disease or disorder or ps US 5,576, 328 discloses in a patient. See abstract Claims 1-8 lack an inver or 5,576, 328 discloses t Claims 1-8 meet the crit osychiatric disease have	Applicability (IA)  DEXPLANATIONS elty under the criteria of PCT discloses the same invention the administration of the inst in a patient. See abstract, col sychiatric disease.  the administration of the inst t, col. 1-5, claims 1-16. Ische mative step under PCT Article	Claims Claims Claims Claims Claims Claims Claims 1 Article 33(2) be n claimed herein stant active computer 1-15, claims 1-1	NONE  1-8  NONE  ecause the cited prior art in the Internal	ational Search Report, US I for inhibiting platelet ause a neurodegenerative I for treating ischemic events
Industrial  2. CITATIONS ANI Claims 1-8 lack of nove 6,117,866 or 5,576, 328 US 6,117,866 discloses aggregation or disorder disease or disorder or ps US 5,576, 328 discloses in a patient. See abstract Claims 1-8 lack an inver or 5,576, 328 discloses t Claims 1-8 meet the crit sychiatric disease have	Applicability (IA)  DEXPLANATIONS elty under the criteria of PCT discloses the same invention the administration of the inst in a patient. See abstract, col sychiatric disease.  the administration of the inst t, col. 1-5, claims 1-16. Ische mative step under PCT Article	Claims Claims Claims Claims Claims Claims Claims 1 Article 33(2) be n claimed herein stant active computer 1-15, claims 1-1	NONE  1-8  1-8  NONE  1-8  NONE  ecause the cited prior art in the International counds in a composition for a method 16. Platelet aggregation is known to compounds in a composition for a method pounds in a composition for a method	YE NO YE NO Ational Search Report, US I for inhibiting platelet ause a neurodegenerative If or treating ischemic events
Industrial  2. CITATIONS ANI Claims 1-8 lack of nove 6,117,866 or 5,576, 328 US 6,117,866 discloses aggregation or disorder disease or disorder or ps US 5,576, 328 discloses in a patient. See abstract Claims 1-8 lack an inver or 5,576, 328 discloses t Claims 1-8 meet the crit sychiatric disease have	Applicability (IA)  DEXPLANATIONS elty under the criteria of PCT discloses the same invention the administration of the inst in a patient. See abstract, col sychiatric disease.  the administration of the inst t, col. 1-5, claims 1-16. Ische mative step under PCT Article	Claims Claims Claims Claims Claims Claims Claims 1 Article 33(2) be n claimed herein stant active computer 1-15, claims 1-1	NONE  1-8  1-8  NONE  1-8  NONE  ecause the cited prior art in the International counds in a composition for a method 16. Platelet aggregation is known to compounds in a composition for a method pounds in a composition for a method	YE  NO  YE  NO  ational Search Report, US  for inhibiting platelet ause a neurodegenerative  d for treating ischemic events
Industrial  2. CITATIONS ANI Claims 1-8 lack of nove 6,117,866 or 5,576, 328 US 6,117,866 discloses aggregation or disorder disease or disorder or ps US 5,576, 328 discloses in a patient. See abstract Claims 1-8 lack an inver or 5,576, 328 discloses t Claims 1-8 meet the crit sychiatric disease have	Applicability (IA)  D EXPLANATIONS elty under the criteria of PCT d discloses the same invention the administration of the inst in a patient. See abstract, col sychiatric disease.  the administration of the inst t, col. 1-5, claims 1-16. Ische ntive step under PCT Article	Claims	NONE  1-8  NONE  ceause the cited prior art in the International counds in a composition for a method 16. Platelet aggregation is known to a pounds in a composition for a method	NC YE NO ational Search Report, US for inhibiting platelet sause a neurodegenerative If for treating ischemic events
Industrial  2. CITATIONS ANI Claims 1-8 lack of nove 6,117,866 or 5,576, 328 US 6,117,866 discloses aggregation or disorder disease or disorder or ps US 5,576, 328 discloses in a patient. See abstract Claims 1-8 lack an inver or 5,576, 328 discloses t Claims 1-8 meet the crit sychiatric disease have	Applicability (IA)  D EXPLANATIONS elty under the criteria of PCT d discloses the same invention the administration of the inst in a patient. See abstract, col sychiatric disease.  the administration of the inst t, col. 1-5, claims 1-16. Ische ntive step under PCT Article	Claims Cl	1-8  NONE  ecause the cited prior art in the International state of the composition for a method 16. Platelet aggregation is known to a pounds in a composition for a method pounds in a composition for a method	NC YE NO ational Search Report, US for inhibiting platelet sause a neurodegenerative If for treating ischemic events
2. CITATIONS ANI Claims 1-8 lack of nove 6,117,866 or 5,576, 328 US 6,117,866 discloses aggregation or disorder disease or disorder or ps US 5,576, 328 discloses in a patient. See abstract Claims 1-8 lack an inver or 5,576, 328 discloses t Claims 1-8 meet the crit baychiatric disease have	D EXPLANATIONS elty under the criteria of PCT discloses the same invention the administration of the inst in a patient. See abstract, col sychiatric disease. In the administration of the inst t, col. 1-5, claims 1-16. Ische mative step under PCT Article	Claims Claims Claims  Article 33(2) be n claimed herein: stant active compul. 1-5, claims 1-1 stant active compenic events is known active events in the contract events in th	NONE  ecause the cited prior art in the International state of the composition for a method 16. Platelet aggregation is known to a pounds in a composition for a method pounds in a composition for a method	YE NO ational Search Report, US for inhibiting platelet ause a neurodegenerative If for treating ischemic events
2. CITATIONS ANI Claims 1-8 lack of nove 6,117,866 or 5,576, 328 US 6,117,866 discloses aggregation or disorder disease or disorder or ps US 5,576, 328 discloses in a patient. See abstract Claims 1-8 lack an inver or 5,576, 328 discloses t Claims 1-8 meet the crit osychiatric disease have	D EXPLANATIONS elty under the criteria of PCT discloses the same invention the administration of the inst in a patient. See abstract, col sychiatric disease. In the administration of the inst t, col. 1-5, claims 1-16. Ische mative step under PCT Article	Claims  CArticle 33(2) be n claimed herein: stant active compol. 1-5, claims 1-1 stant active compenic events is known in the compenic events in the compenic events is known in the compenic events in the	NONE  ecause the cited prior art in the Internation  oounds in a composition for a method  16. Platelet aggregation is known to composition for a method	no No ational Search Report, US I for inhibiting platelet ause a neurodegenerative
2. CITATIONS ANI Claims 1-8 lack of nove 6,117,866 or 5,576, 328 US 6,117,866 discloses aggregation or disorder disease or disorder or ps US 5,576, 328 discloses in a patient. See abstract Claims 1-8 lack an inver or 5,576, 328 discloses t Claims 1-8 meet the crit baychiatric disease have	D EXPLANATIONS elty under the criteria of PCT discloses the same invention the administration of the inst in a patient. See abstract, col sychiatric disease. In the administration of the inst t, col. 1-5, claims 1-16. Ische mative step under PCT Article	Claims  CArticle 33(2) be n claimed herein: stant active compol. 1-5, claims 1-1 stant active compenic events is known in the compenic events in the compenic events is known in the compenic events in the	NONE  ecause the cited prior art in the Internation  oounds in a composition for a method  16. Platelet aggregation is known to composition for a method	no No ational Search Report, US I for inhibiting platelet ause a neurodegenerative
Claims 1-8 lack of nove 6,117,866 or 5,576, 328 US 6,117,866 discloses aggregation or disorder disease or disorder or ps US 5,576, 328 discloses in a patient. See abstract Claims 1-8 lack an inversor 5,576, 328 discloses t Claims 1-8 meet the critosychiatric disease have	elty under the criteria of PCT discloses the same invention the administration of the instina patient. See abstract, colsychiatric disease.  In the administration of the institute of the institute disease.  In the administration of the institute of the institut	Article 33(2) be on claimed herein: stant active composite 1-5, claims 1-1 stant active compenic events is known is known active compenic events in active compenic events is known active events in active compenic events in active compenic events in active event event events in active event ev	ecause the cited prior art in the Internation of the composition for a method 16. Platelet aggregation is known to composition for a method pounds in a composition for a method	ational Search Report, US for inhibiting platelet ause a neurodegenerative I for treating ischemic events
Claims 1-8 lack of nove 6,117,866 or 5,576, 328 US 6,117,866 discloses aggregation or disorder disease or disorder or ps US 5,576, 328 discloses in a patient. See abstract Claims 1-8 lack an inversor 5,576, 328 discloses to Claims 1-8 meet the critissychiatric disease have	elty under the criteria of PCT discloses the same invention the administration of the instina patient. See abstract, colsychiatric disease.  In the administration of the institute of the institute disease.  In the administration of the institute of the institut	on claimed herein: stant active composite 1-5, claims 1-1 stant active composite active composite stant active composite events is known in the composite stant active stant a	n:  counds in a composition for a method  16. Platelet aggregation is known to composition for a method  pounds in a composition for a method	for inhibiting platelet sause a neurodegenerative
	the same invention claimed heria of PCT Article 33(4) be industrial applicability in the CITATIONS	herein, as discuss cause the claimed the pharmaceutical	sed above.  ed methods of treating a neurodegener	•
		•		
				•
			·	
•				

Form PCT/IPEA/409 (Box V) (July 1998)

## **PCT**

### NOTE OF INFORMAL COMMUNICATION WITH THE APPLICANT

(PCT Rule 66.6)

International application	ı No.	Applicant's or agent's	file reference	Date of informal communication			
PCT/US03/33022		PENN-0858		(day/month/year) 16 May 2005 (16.05.2005)			
Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA							
	1		Identity	authorization personally			
Communication	<u>Participants</u>		checked	checked personally known			
by telephone	Applicant:	THE TRUSTEES	OF THE UNIVERS	ITY OF PENNSYLVANIA			
personal	Agent:	Jane Licata					
	Examiner(	s): Shaojia A. Jiang					
Summary of communicat	tion:						
Preliminary Examination	Upon request by the examiner, applicant's representative Jane Licata agreed to proceed to the 409 the International Preliminary Examination Report, directly in order to meet the administrative deadlines for the instant application and/or expedite the PCT process.						
•							
				·			
An extension of time limit is granted (Form PCT/IPEA/427.							
A copy of this note is being sent to the applicant with Form PCT/IPEA/429.  PCT/IPEA/424.							
Name and mailing address	of the IPEA/US						
Mail Stop PCT, At	tn: IPEA/US		Authorized office	Danice toul			
Commissioner for l P.O. Box 1450	ratents		Sreeni Padmanal	bhan Juli			
Alexandria, Virgini Pacsimile No. (703) 305-32			Telephone No. 5	bhan Janese Ford 71.272.1600			

Form PCT/IPEA/428 (July 1992)